IndustriesIn Vitro & In Vivo Diagnostic Substances

In Vitro & In Vivo Diagnostic Substances

Open in the Screener

Companies

Median grade

4.96

Highest

IDXX 7.47

Lowest

QCLS 3.07

A grade ranks a company against its own industry, from its filings. It is not a view on the share price. 18 of 5,495 companies on file are in this industry.

Company, by grade	Grade	◀ Past	● Present	▶ Future	Arc	Filed
1IDXXIDEXX Laboratories, Inc.	7.47	8.8	7.8	5.7	Falling	9 of 9
2LNTHLantheus Holdings, Inc.	6.76	8.7	7.1	4.5	Falling	9 of 9
3MYGNMyriad Genetics, Inc.	6.05	6.7	5.7	5.8	Falling	8 of 9
4NTLAIntellia Therapeutics, Inc.	6.05	6.9	5.9	5.4	Falling	8 of 9
5NNNNAnbio Biotechnology	5.72	4.4	6.1	6.3	Rising	8 of 9
6NEOGNeogen Corporation	5.52	6.3	5.8	4.3	Falling	9 of 9
7ICCCImmuCell Corporation	5.25	4.8	5.8	4.9	Rising	8 of 9
8TKNOAlpha Teknova, Inc.	5.21	5.8	5.7	3.9	Falling	8 of 9
9CLDXCelldex Therapeutics, Inc.	5.12	3.8	6.0	5.1	Rising	8 of 9
10CDIOCardio Diagnostics Holdings Inc.	4.80	3.4	4.6	5.8	Rising	8 of 9
11QDELQuidelOrtho Corporation	4.79	5.8	5.0	3.6	Falling	9 of 9
12IMDXInsight Molecular Diagnostics Inc.	4.74	3.6	2.9	7.1	Rising	8 of 9
13ACHVAchieve Life Sciences, Inc.	4.59	4.2	3.1	6.2	Rising	3 of 9
14VNRXVolitionRx Limited	4.31	3.8	4.7	4.3	Rising	8 of 9
15TRIBTrinity Biotech plc	4.09	4.1	3.6	4.7	Rising	7 of 9
16BMRABiomerica, Inc.	3.69	3.2	3.5	4.2	Rising	8 of 9
17VRAXVirax Biolabs Group Limited	3.34	3.0	3.0	3.9	Rising	7 of 9
18QCLSQ/C Technologies, Inc.	3.07	1.3	2.5	4.7	Rising	6 of 9

New in the recordsince Oct 30, 2026

Nov 13ICCCReleased results 8-K
Nov 12ICCCFiled its quarterly report 10-Q
Nov 12NTLAReleased results 8-K
Nov 12VNRXFiled its quarterly report 10-Q
Nov 12VNRXReleased results 8-K
Nov 12VNRXReported an officer or director change 8-K
Nov 10ACHVFiled its quarterly report 10-Q
Nov 10ACHVReleased results 8-K
Nov 9MYGNReported an officer or director change 8-K
Nov 6CDIOFiled its quarterly report 10-Q
Nov 6MYGNFiled its quarterly report 10-Q
Nov 5CLDXReleased results 8-K

Filings read from SEC EDGAR, as of Nov 13, 2026.

Next deadlinesfrom the SEC's rules

Nov 14IMDX10-Q due under the SEC's rules, the quarterly report for the period ended 2026-09-30
Nov 14QCLS10-Q due under the SEC's rules, the quarterly report for the period ended 2026-09-30
Jan 9NEOG10-Q due under the SEC's rules, the quarterly report for the period ended 2026-11-30
Jan 14BMRA10-Q due under the SEC's rules, the quarterly report for the period ended 2026-11-30
Mar 1CLDX10-K due under the SEC's rules, the annual report for the period ended 2026-12-31
Mar 1IDXX10-K due under the SEC's rules, the annual report for the period ended 2026-12-31
Mar 1LNTH10-K due under the SEC's rules, the annual report for the period ended 2026-12-31
Mar 1NTLA10-K due under the SEC's rules, the annual report for the period ended 2026-12-31
Mar 2QDEL10-K due under the SEC's rules, the annual report for the period ended 2027-01-01

A deadline is the rule's date for the filer's category, never a prediction.

SI Assistanton In Vitro & In Vivo Diagnostic Substances · research, not advice